John Dulos

856 total citations
22 papers, 673 citations indexed

About

John Dulos is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, John Dulos has authored 22 papers receiving a total of 673 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in John Dulos's work include Cytokine Signaling Pathways and Interactions (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Melanoma and MAPK Pathways (3 papers). John Dulos is often cited by papers focused on Cytokine Signaling Pathways and Interactions (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Melanoma and MAPK Pathways (3 papers). John Dulos collaborates with scholars based in Netherlands, United States and Denmark. John Dulos's co-authors include Annemieke M. H. Boots, Hans van Eenennaam, A. Boots, Anton F. J. de Haan, Willemijn Hobo, Peter F.A. Mulders, Egbert Oosterwijk, Cornelis J. A. Punt, Gregory J. Carven and Monika Górecka and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

John Dulos

21 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Dulos Netherlands 14 300 259 196 83 65 22 673
Julie A. Lucas United States 14 353 1.2× 695 2.7× 217 1.1× 52 0.6× 49 0.8× 16 1.1k
Urmi Dhagat Australia 14 122 0.4× 268 1.0× 203 1.0× 26 0.3× 68 1.0× 27 697
Paraskevi Kotsi Greece 10 141 0.5× 217 0.8× 428 2.2× 36 0.4× 89 1.4× 19 725
Chris Planque France 15 197 0.7× 121 0.5× 297 1.5× 49 0.6× 76 1.2× 20 624
Rocky Pramanik United States 14 170 0.6× 143 0.6× 292 1.5× 71 0.9× 34 0.5× 18 613
Gabriella Regis Italy 10 326 1.1× 255 1.0× 235 1.2× 29 0.3× 48 0.7× 10 627
Veerle Fleskens Netherlands 12 140 0.5× 352 1.4× 381 1.9× 66 0.8× 43 0.7× 13 749
Marie‐Thérèse Simon France 12 179 0.6× 105 0.4× 210 1.1× 82 1.0× 19 0.3× 12 665
Diego Maritano Italy 7 415 1.4× 297 1.1× 296 1.5× 39 0.5× 51 0.8× 9 772
Jürgen Steffgen Germany 14 145 0.5× 146 0.6× 228 1.2× 57 0.7× 24 0.4× 25 639

Countries citing papers authored by John Dulos

Since Specialization
Citations

This map shows the geographic impact of John Dulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Dulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Dulos more than expected).

Fields of papers citing papers by John Dulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Dulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Dulos. The network helps show where John Dulos may publish in the future.

Co-authorship network of co-authors of John Dulos

This figure shows the co-authorship network connecting the top 25 collaborators of John Dulos. A scholar is included among the top collaborators of John Dulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Dulos. John Dulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dulos, John, et al.. (2025). ADAMTS-5 inhibition reduces muscle inflammation and fibrosis and improves function in mouse models of Duchenne muscular dystrophy. Science Translational Medicine. 17(803). eado2112–eado2112.
2.
Kooienga, Laura, Eun Young Lee, Sung Gyun Kim, et al.. (2025). Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy. Kidney International. 108(3). 445–454. 1 indexed citations
3.
Tai, Yu‐Tzu, Liang Lin, Lijie Xing, et al.. (2018). APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 33(2). 426–438. 66 indexed citations
4.
Bree, L. Charlotte J. de, Renoud J. Marijnissen, Junda M. Kel, et al.. (2018). Bacillus Calmette–Guérin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice. Frontiers in Immunology. 9. 2471–2471. 30 indexed citations
6.
Dulos, John, J.A.C. Rullmann, Paul Vink, et al.. (2013). p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes.. PubMed. 31(4). 515–25. 15 indexed citations
7.
Dulos, John, Gregory J. Carven, Willemijn Hobo, et al.. (2012). PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. Journal of Immunotherapy. 35(2). 169–178. 259 indexed citations
8.
Marijnissen, Renoud J., Marije I. Koenders, Frank L. van de Veerdonk, et al.. (2012). Exposure to Candida albicans Polarizes a T-Cell Driven Arthritis Model towards Th17 Responses, Resulting in a More Destructive Arthritis. PLoS ONE. 7(6). e38889–e38889. 16 indexed citations
9.
Kaptein, Allard, Arthur Oubrie, Edwin de Zwart, et al.. (2011). Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(12). 3823–3827. 17 indexed citations
10.
Koenders, Marije I., Renoud J. Marijnissen, Leo A. B. Joosten, et al.. (2011). T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3‐rich synovium lacks response to CTLA‐4ig but is successfully treated by interleukin‐17 neutralization. Arthritis & Rheumatism. 64(6). 1762–1770. 21 indexed citations
11.
Dulos, John, et al.. (2010). Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor α but not estrogen receptor β. Arthritis Research & Therapy. 12(3). R101–R101. 26 indexed citations
12.
Dulos, John, Karin J. Stebbins, Jörg Hamann, et al.. (2009). Therapeutic Antibody Targeting of CD97 in Experimental Arthritis: the Role of Antigen Expression, Shedding, and Internalization on the Pharmacokinetics of Anti-CD97 Monoclonal Antibody 1B2. The Journal of Immunology. 183(6). 4127–4134. 30 indexed citations
13.
Almansa, Carmen, Ruben L. Smeets, Elma E.M.G. Loomans, et al.. (2008). A potent and selective p38 inhibitor protects against bone damage in murine collagen‐induced arthritis: a comparison with neutralization of mouse TNFα. British Journal of Pharmacology. 154(1). 153–164. 46 indexed citations
14.
Dulos, John, Claudia L. Hofstra, Leo A. B. Joosten, et al.. (2006). A selective estrogen receptor alpha agonist (ORG 37663) suppresses inflammation and arthritis in mouse models. Annals of the Rheumatic Diseases. 65. 128–128. 3 indexed citations
15.
Dulos, John, et al.. (2006). DHEA Metabolism in Arthritis. Annals of the New York Academy of Sciences. 1069(1). 401–413. 13 indexed citations
16.
Dulos, John, Allard Kaptein, Annemieke Kavelaars, Cobi J. Heijnen, & Annemieke M. H. Boots. (2005). Tumour necrosis factor-α stimulates dehydroepiandrosterone metabolism in human fibroblast-like synoviocytes: a role for nuclear factor-κB and activator protein-1 in the regulation of expression of cytochrome p450 enzyme 7b. Arthritis Research & Therapy. 7(6). R1271–80. 17 indexed citations
17.
19.
Dulos, John, et al.. (1992). A study on cell lineage, especially the germ cell line, in embryos of the teleost fish,Barbus conchonius. Development Genes and Evolution. 201(5). 275–283. 8 indexed citations
20.
Dulos, John, et al.. (1992). Origin of primordial germ cells, as characterized by the presence of nuage, in embryos of the teleost fish Barbus conchonius.. PubMed. 30(3). 195–204. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026